Navigation Links
Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
Date:1/9/2012

ROCKVILLE, Md., Jan. 9, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announces that President and CEO Richard Garr will present at the 2012 Biotech Showcase in San Francisco on Tuesday, January 10, 1:45-3:00pm PT. Garr will serve on the Therapeutic Focus Panel entitled, "Neurodegenerative Disease, Ophthalmology and Spinal Injury," featured in the Alliance for Regenerative Medicine (ARM) Insight Track. Garr will also present a business overview, including an update on the world's first FDA-approved stem cell injections in the cervical region, in its ongoing ALS cell therapy Phase I trial. He will also present an update on the recently FDA-approved advancement to Phase Ib dosing in depressed patients of its first-in-class NSI-189 small molecule drug, in its ongoing NSI-189/major depressive disorder (MDD) trial.

(Logo:  http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

The 2012 Biotech Showcase will be held at the Parc 55 Wyndham Hotel in San Francisco, January 9-11. For more information, see: http://www.ebdgroup.com/bts/index.php. Biotech Showcase runs concurrently to the world's largest annual healthcare investor conference, and provides private and public life science companies the opportunity to present to an audience of investors and business development executives interested in innovative biotech companies.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosi
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
2. Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
3. Neuralstem President and CEO to Present at the 2011 Stifel Nicolaus Annual Healthcare Conference
4. Neuralstem Awarded Department of Defense Contract for Brain Cancer Research
5. Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update
6. Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstems Board
7. Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd.
8. Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine Congress
9. Neuralstem Completes $5.25 Million Financing
10. Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
11. Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a ... target the underlying mechanisms of cancer, today reported financial ... 31, 2014. Effective July 17, 2014, the ... to December 31. As a result of that change, ... quarter and the seven months ended December 31, 2014, ...
(Date:3/3/2015)... NASA astronaut Scott Kelly , who is ... a year living and working on the International Space Station, ... 7 a.m. EDT Monday, March 9. Kelly will ... the final weeks of his training. The interviews will be ... highlighting his mission training and previous spaceflights. To ...
(Date:3/3/2015)... BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced several ... projects in North America , the ... "Bidding activity in 2015 continues to be robust" said ... year for bidding in 2014, we are pleased to see the ... the organization,s renewed focus on select market segments where we can ...
(Date:3/3/2015)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... Executive Officer of Neurocrine Biosciences, will be presenting at ... The live presentation takes place on Tuesday, March ... be webcast and may be accessed on the Company,s ... are encouraged to visit the website approximately 5 minutes ...
Breaking Biology Technology:Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2
... BERKELEY HEIGHTS, N.J., Oct. 18 Genta,Incorporated (Nasdaq: ... preclinical,data on Genasense(R) (oblimersen sodium) Injection, its lead ... and Therapeutics",conference that will take place from October ... is jointly sponsored by the U.S. National Cancer,Institute ...
... Consortium today published analyses of its second-generation map ... more markers than the initial version unveiled in ... the consortium describes how the higher resolution map ... in common diseases, explore the structure of human ...
... BioMarin,Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced ... dihydrochloride), Naglazyme(R),(galsulfase), and Aldurazyme(R) (laronidase) will be presented ... of Human Genetics in San Diego,California, October 23-27, ... below:, Platform Presentation - Session 59 - ...
Cached Biology Technology:Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC 'Targets' Conference 2Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC 'Targets' Conference 3Consortium publishes Phase II map of human genetic variation 2Consortium publishes Phase II map of human genetic variation 3Consortium publishes Phase II map of human genetic variation 4Consortium publishes Phase II map of human genetic variation 5Consortium publishes Phase II map of human genetic variation 6Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics 2Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics 3Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics 4
(Date:2/24/2015)... NEW YORK , Feb. 24, 2015 This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... America . Annual estimates and forecasts are provided for ... is provided for these markets. Market data and analytics are ...
(Date:2/19/2015)... 2015 Research and Markets ( ... "Military Electro-Optical / Infrared Systems Market by ... - Forecast to 2020" report to their ... market is expected to reach $16.35 billion by ... This report segments the military electro-optical/infrared systems ...
(Date:2/12/2015)... , Feb. 12, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... filed provisional patent 62/113114 for DISTRIBUTED METHOD ... The patent further establishes NXT-ID,s position in ... intellectual property portfolio the ability for multiple devices to ...
Breaking Biology News(10 mins):World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3
... Bacteria normally found 30km above the earth have been ... stratosphericus a microbe commonly found in high concentrations ... is a key component of a new ,super, biofilm that ... University. , Isolating 75 different species of bacteria from the ...
... muscle . . . ,Researchers at the Bio-SANS ... variation and small-angle neutron scattering to get a first ... synthetic complexes. The unique properties of polyelectrolyte materials are ... of membrane -- three-dimensional bio-scaffolds to grow cells for ...
... One of the greatest biological threats to tropical coral reefs ... ( Acanthaster planci ). Outbreaks can consume live corals over ... reef fish populations, and reduce the aesthetic value of coral ... 30 years of research, the triggers and spread of COT ...
Cached Biology News:Superbugs from space offer new source of power 2Feb. 21, 2012, story tips 2Feb. 21, 2012, story tips 3Coral-eating sea star invaders turn out to be locals 2
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Zinc finger MYM-type protein 3 (Zinc finger protein 261) (DXS6673E protein). [Source:Uniprot/SWISSPROT;Acc:Q14202] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Human Ig Lambda-chain, clone ICO-16, Monoclonal Antibody...
Biology Products: